Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells

American Journal of Clinical Pathology

Volumn 141, Issue 1, 2014, Pages 85-93

  Minato, Hiroshi ^a   Kurose, Nozomu ^a   Fukushima, Mana ^a   Nojima, Takayuki ^a   Usuda, Katsuo ^a   Sagawa, Motoyasu ^a   Sakuma, Tsutomu ^a   Ooi, Akishi ^b   Matsumoto, Isao ^b   Oda, Makoto ^b   Arano, Yoshihiko ^c   Shimizu, Junzo ^c  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KKR Hokuriku Hospital   (Japan)

Author keywords

CD146; Desmin; EMA; GLUT1; Immunohistochemistry; IMP3; Malignant mesothelioma; Reactive mesothelial cell

Indexed keywords

BINDING PROTEIN; BIOLOGICAL MARKER; CD146 ANTIGEN; DESMIN; EPITHELIAL MEMBRANE ANTIGEN; GLUCOSE TRANSPORTER 1; INSULIN LIKE GROWTHFACTOR 2 MESSENGER RNA BINDING PROTEIN 3; UNCLASSIFIED DRUG; IMP3 PROTEIN, HUMAN; MCAM PROTEIN, HUMAN; MUCIN 1; RNA BINDING PROTEIN; SLC2A1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REACTIVE MESOTHELIAL CELL; SENSITIVITY AND SPECIFICITY; ADOLESCENT; CHEMISTRY; EPITHELIUM CELL; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; VERY ELDERLY; CD146; EMA; IMP3; LUNG TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD146; BIOMARKERS, TUMOR; DESMIN; EPITHELIAL CELLS; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; MUCIN-1; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

CD146; DESMIN; EMA; GLUT1; IMMUNOHISTOCHEMISTRY; IMP3; MALIGNANT MESOTHELIOMA; REACTIVE MESOTHELIAL CELL;

EID: 84894558597     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP5KNL7QTELLYI     Document Type: Article

References (25)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591-1603. (Pubitemid 41434638)
2. Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136:888-896.
3. Cury PM, Butcher DN, Corrin B, et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol. 1999;189:251-257. (Pubitemid 29448921)
4. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol. 2000;24:1183-1200.
5. King J, Thatcher N, Pickering C, et al. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology. 2006;49:561-568. (Pubitemid 44924287)
6. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20:215-220. (Pubitemid 46422176)
7. Sato A, Torii I, Okamura Y, et al. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium. Mod Pathol. 2010;23:1458-1466.
8. Shi M, Fraire AE, Chu P, et al. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol. 2011;35:878-882.
9. Findeis-Hosey JJ, Xu H. The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol. 2011;42:303-314.
10. Hanley KZ, Facik MS, Bourne PA, et al. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer. 2008;114:49-56. (Pubitemid 351304612)
11. Ikeda K, Tate G, Suzuki T, et al. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Diagn Cytopathol. 2011;39:395-401.
12. Olson AL, Pessin JE. Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr. 1996;16:235-256. (Pubitemid 26286854)
13. Monaco SE, Shuai Y, Bansal M, et al. The diagnostic utility of pl6 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011;135:619-627.
14. Shen J, Pinkus GS, Deshpande V, et al. Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol. 2009;131:516-523.
15. Bidlingmaier S, He J, Wang Y, et al. Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res. 2009;69:1570-1577.
16. Shih IM, Nesbit M, Herlyn M, et al. A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue. Mod Pathol. 1998;11:1098-1106. (Pubitemid 28525017)
17. Beck JR, Shultz EK. The use of relative operating characteristic (ROC) curves in test performance evaluation. Arch Pathol Lab Med 1986;110:13-20. (Pubitemid 16011804)
18. Pinheiro C, Longatto-Filho A, Soares TR, et al. CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma. Diagn Cytopathol. 2012;40:478-483.
19. Onofre FB, Onofre AS, Pomjanski N, et al. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer. 2008;114:204-215. (Pubitemid 351969240)
20. Chiosea S, Krasinskas A, Cagle PT, et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008;21:742-747. (Pubitemid 351744840)
21. Takeda M, Kasai T, Enomoto Y, et al. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int. 2010;60:395-399.
22. Chung CT, Santos Gda C, Hwang DM, et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol. 2010;63:630-634.
23. Dacic S, Kothmaier H, Land S, et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. 2008;453:627-635.
24. Savic S, Franco N, Grilli B, et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest. 2010;138:137-144.
25. Takeda M, Kasai T, Enomoto Y, et al. Genomic gains and losses in malignant mesothelioma demonstrated by FISH analysis of paraffin-embedded tissues. J Clin Pathol. 2012;65:77-82.